Research analysts at Evercore ISI initiated coverage on shares of bluebird bio, Inc. (NASDAQ:BLUE) in a note issued to investors on Wednesday, The Fly reports. The firm set a $102.00 price target on the biotechnology company’s stock. Evercore ISI’s target price would indicate a potential upside of 5.05% from the stock’s previous close.

Other analysts have also issued research reports about the company. Cantor Fitzgerald set a $39.00 price objective on bluebird bio and gave the company a “sell” rating in a research note on Saturday, June 24th. Jefferies Group LLC restated a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Sanford C. Bernstein assumed coverage on bluebird bio in a research note on Thursday, July 27th. They issued a “market perform” rating and a $109.00 price objective on the stock. BMO Capital Markets restated a “buy” rating and issued a $108.00 price objective on shares of bluebird bio in a research note on Friday, August 4th. Finally, Morgan Stanley restated a “hold” rating on shares of bluebird bio in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $100.74.

Shares of bluebird bio (NASDAQ BLUE) traded up 0.05% on Wednesday, reaching $97.10. The company’s stock had a trading volume of 337,179 shares. bluebird bio has a 1-year low of $37.05 and a 1-year high of $123.75. The firm’s market cap is $4.43 billion. The company’s 50 day moving average is $97.68 and its 200-day moving average is $90.84.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.66) by $0.07. The business had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. bluebird bio’s quarterly revenue was up 977.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.59) EPS. Equities research analysts expect that bluebird bio will post ($6.78) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “bluebird bio, Inc. (BLUE) Research Coverage Started at Evercore ISI” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/bluebird-bio-inc-blue-research-coverage-started-at-evercore-isi.html.

In other bluebird bio news, Director Daniel Lynch sold 2,500 shares of the firm’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $120.03, for a total transaction of $300,075.00. Following the transaction, the director now owns 5,300 shares in the company, valued at approximately $636,159. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider David Davidson sold 1,000 shares of the firm’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $90.00, for a total value of $90,000.00. Following the transaction, the insider now owns 18,177 shares in the company, valued at approximately $1,635,930. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 80,106 shares of company stock worth $8,308,358. Corporate insiders own 3.90% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. raised its position in bluebird bio by 5.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,600 shares of the biotechnology company’s stock worth $378,000 after buying an additional 191 shares during the period. Fairfield Bush & CO. bought a new position in bluebird bio during the second quarter worth approximately $210,000. Raymond James Financial Services Advisors Inc. bought a new position in bluebird bio during the second quarter worth approximately $211,000. The Manufacturers Life Insurance Company raised its position in bluebird bio by 0.5% in the second quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock worth $3,302,000 after buying an additional 151 shares during the period. Finally, Alpine Global Management LLC bought a new position in bluebird bio during the second quarter worth approximately $410,000.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

The Fly

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.